Department of Cell Biology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, USA.
J Cell Biochem. 2012 Apr;113(4):1368-76. doi: 10.1002/jcb.24009.
JMJD2A is a transcriptional cofactor and enzyme that catalyzes demethylation of histone H3 lysines 9 and 36 and is overexpressed in human tumors, but its role in oncogenesis remains unclear. Here, we show that JMJD2A interacts with the tumor suppressor p53 both in vitro and in HCT116 colon cancer cells. Chromatin immunoprecipitation assays demonstrated that JMJD2A was recruited together with p53 to the promoter of the p21 cell cycle inhibitor upon stimulation with the DNA damaging agent, adriamycin. Downregulation of JMJD2A resulted in increased expression of p21 and of the pro-apoptotic Puma protein, whereas levels of the anti-apoptotic Bcl-2 protein were decreased. Furthermore, JMJD2A knock-down led to reduced HCT116, DLD-1 and HT-29 colon cancer cell proliferation, while overexpression of JMJD2A enhanced HCT116 proliferation in low serum media. Finally, JMJD2A depletion induced apoptosis in HCT116 cells and this effect was less pronounced in the absence of p53. Collectively, these data indicate that JMJD2A is a novel promoter of colon cancer cell proliferation and survival, which mediates its effects in p53-dependent and -independent ways. JMJD2A may therefore be a valid target to sensitize tumor cells to chemotherapy-induced cell death and growth suppression.
JMJD2A 是一种转录共因子和酶,可催化组蛋白 H3 赖氨酸 9 和 36 的去甲基化,在人类肿瘤中过度表达,但它在肿瘤发生中的作用仍不清楚。在这里,我们表明 JMJD2A 在体外和 HCT116 结肠癌细胞中均与肿瘤抑制因子 p53 相互作用。染色质免疫沉淀试验表明,在 DNA 损伤剂阿霉素刺激下,JMJD2A 与 p53 一起被募集到 p21 细胞周期抑制剂的启动子上。JMJD2A 的下调导致 p21 和促凋亡 Puma 蛋白的表达增加,而抗凋亡 Bcl-2 蛋白的水平降低。此外,JMJD2A 的敲低导致 HCT116、DLD-1 和 HT-29 结肠癌细胞增殖减少,而 JMJD2A 的过表达增强了低血清培养基中 HCT116 的增殖。最后,JMJD2A 的耗竭诱导 HCT116 细胞凋亡,而在没有 p53 的情况下,这种效应不那么明显。总之,这些数据表明 JMJD2A 是结肠癌增殖和存活的新型启动子,它以 p53 依赖和非依赖的方式发挥其作用。因此,JMJD2A 可能是使肿瘤细胞对化疗诱导的细胞死亡和生长抑制敏感的有效靶点。